Tranilast (N-(3 0 4 0 -demethoxycinnamoyl)-anthranilic acid (N-5)) is an investigational drug for the prevention of restenosis following percutaneous transluminal coronary revascularization. An increase in bilirubin levels was observed in 12% of patients upon administration of tranilast in a phase III clinical trial. To identify the potential genetic factors that may account for the drug-induced hyperbilirubinemia, we examined polymorphisms in the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene in over a thousand patients. Our results suggested that the TA repeat polymorphism in UGT1A1, which predisposes some individuals to Gilbert's syndrome, predicted the susceptibility to tranilast-induced hyperbilirubinemia. The (TA) 7 /(TA) 7 genotype was present in 39% of the 127 hyperbilirubinemic patients vs 7% of the 909 controls (P ¼ 2 Â 10 À22 ). Rapid identification of genetic factors accounting for the observed adverse effect during the course of a double-blind clinical trial demonstrated the potential application of pharmacogenetics in the clinical development of safe and effective medicines.
INTRODUCTION
Percutaneous transluminal coronary revascularization (PTCR) is widely used for the treatment of ischemic heart disease; however, restenosis requiring repeat procedures remains problematic. In the 6 months following successful PTCR, restenosis may occur in up to 50% of patients. 1 Tranilast (N-(3 0 4 0 -demethoxycinnamoyl)-anthranilic acid (N-5)) is an antiallergic compound, clinically effective in the control of autoimmune disease such as bronchial asthma and atoptic dermatitis. Based on previous clinical trials, 2 tranilast was hypothesized to be effective in reducing the frequency of cardiovascular events and angiographic restenosis in patients undergoing PTCR. The PRESTO (Prevention of REStenosis with Tranilast and its Outcomes) study was designed to determine the safety and efficacy of tranilast in the prevention of restenosis after PTCR in Western populations. 3 During this phase III clinical trial, hyperbilirubinemia, characterized by raised unconjugated serum bilirubin levels, was observed in approximately 12% of patients. The etiology of this mild elevation in serum bilirubin level was unknown, but raised risks of major hepatic complications associated with tranilast.
Serum bilirubin is derived primarily from degradation of hemoglobin and transported to the liver by binding to albumin. Within the heptocytes, uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) is the only enzyme that contributes to bilirubin glucuronidation. 4 Glucuronidation is essential for the biliary elimination of bilirubin, and deficiencies in the UGT1A1 gene result in the accumulation of unconjugated bilirubin in the serum. In humans, there are at least three forms of inheritable hyperbilirubinemia caused by deficiencies of UGT1A1. Crigler-Najjar syndrome type 1 is characterized by lethal hyperbilirubinemia, 5 and is caused by complete lack of UGT1A1 activity. 6 Left untreated, Crigler-Najjar syndrome type 1 results in death from bilirubin encephalopathy. Crigler-Najjar syndrome type 2 is differentiated by the intermediate levels of hyperbilirubinemia, and is the result of severe deficiencies in UGT1A1 activity (B10% of normal activities). The incidences of both syndromes are very rare. 7, 8 A third condition, Gilbert's syndrome, 9 is characterized by mild hyperbilirubinemia, and is a benign form of episodic jaundice that occurs in approximately 3-10% of the population.
10,11 Gilbert's syndrome is thought to be harmless and often goes undetected. Baseline bilirubin levels of Gilbert's syndrome patients are generally within normal limits. Episodes of hyperbilirubinemia can be brought on by a number of triggers such as psychological stress, infection, fasting and physical activities. 10, 11 Hepatic UGT1A1 activity in individuals with Gilbert's syndrome is approximately 30% that of normal healthy individuals. 12 Several studies have demonstrated that the genetic predisposition to Gilbert's syndrome is associated with a TA repeat expansion in the TATAA box of the UGT1A1 gene. [13] [14] [15] Individuals homozygous for the (TA) 7 allele have higher serum bilirubin levels when compared to individuals who carry one or more copy of the (TA) 6 allele. 13, [15] [16] [17] Reporter construct analysis showed that the activity of the A(TA) 7 TAA promoter was approximately 18-33% that of the wild-type construct. 13 Furthermore, in vivo experiments demonstrated that the hepatic bilirubin UGT activity was reduced in (TA) 7 homozygotes. 18 The frequency of the (TA) 7 allele is 30-40% in Caucasians, 13, 15, 17, 19 while it is less frequent in the Japanese population, with the frequency being approximately 16%. 20, 21 It was suggested that the GLY71Arg polymorphism may contribute to Gilbert's syndrome, particularly in Japanese and Asian patients. 14, 22, 23 Given these data, we set out to investigate the possible association of both the TA repeat and the GLY71Arg polymorphisms within UGT1A1, with hyperbilirubinemia observed during repeat dosing with tranilast in the PRESTO cohort. Our results supported the hypothesis that genetic predisposition to Gilbert's syndrome predicted susceptibility to hyperbilirubinemia following administration of tranilast.
RESULTS
Genotype results for the TA repeat polymorphism of UGT1A1 were generated for 1042 patients. The allele frequencies for (TA) 5 , (TA) 6 , (TA) 7 and (TA) 8 were 0.001, 0.67, 0.33 and 0.001, respectively. The (TA) 5 allele appears to function normally, while the (TA) 8 allele, similar to the (TA) 7 allele, is associated with Gilbert's syndrome. 19 Six individuals who had either the (TA) 5 or the (TA) 8 allele were excluded due to their low frequencies, with 1036 individuals remaining in subsequent analysis.
Significant differences in genotype distributions were found between cases (bilirubin levels 42.00 mg/dl) and controls (bilirubin levels p2.00 mg/dl) ( Table 1 ,
). In all, 39% of the 127 cases carried the (TA) 7 /(TA) 7 genotype, in comparison with only 7% of the 909 controls. These data predicted an odds ratio of 8.2 for cases vs controls, in relation to (TA) 7 homozygotes vs any other TA genotypes. Genotype frequencies of the TA repeat polymorphism between the same hyperbilirubinemia cases and the super controls (bilirubin levels p1.00 mg/dl) were also compared (Table 1 
). Only 3% of the 541 super controls had the (TA) 7 /(TA) 7 genotype. These data predicted an odds ratio of 22.8 for the cases vs the super controls, in relation to (TA) 7 homozygotes vs any other TA genotypes. It is interesting to note that the level of significance increased from 10 À22 to 10 À33 , even though the number of controls reduced from 909 to 541 in the super control subset, illustrating the impact of using 'stringently' instead of 'loosely' defined control groups on the power of association studies. These findings agreed with the observations discussed by Schork et al, 24 who described the importance of the definition of the control subjects, and Super control is a subset of the control set.
c Data from six of the 1042 patients are not shown, who had either the (TA) 5 or the (TA) 8 allele.
Genetic susceptibility to tranilast-induced hyperbilirubinemia TM Danoff et al how power decreases as less extreme control sample thresholds are used. Thus the analysis of the extremes (low and high) may increase the ability to detect sensitive and specific variants in smaller phase II clinical trials. The mean serum bilirubin level of the 1036 subjects was 0.5770.01 mg/dl before tranilast administration, and increased to 1.2870.03 mg/dl after tranilast. The average bilirubin level increased from 0.53 to 1.00 mg/dl in controls and from 0.46 to 0.74 mg/dl in super controls, and increased from 0.91 to 3.24 mg/dl in cases (Figure 1) . The average bilirubin level varied as a function of the TA repeat genotypes, with the (TA) 7 allele being associated with higher levels of bilirubin level both pre-and post-tranilast administration. The average bilirubin level increased from 0.93 to 2.22 mg/dl in (TA) 7 homozygotes, while it increased from 0.48 to 1.01 mg/dl in (TA) 6 homozygotes and 0.58 to 1.31 mg/dl in heterozygotes. Figure 2 showed the increases in bilirubin levels according to genotypes of the TA repeat polymorphism.
Four individuals were found to be heterozygous for the G/A substitution, giving rise to a frequency of 0.16% for the GLY71Arg change in this sample. These four individuals were homozygous for the (TA) 6 allele for the TA repeat polymorphism. All four individuals were in the control group, suggesting that the GLY71Arg polymorphism was not associated with the observed hyperbilirubinemia after tranilast administration in this Caucasian sample.
DISCUSSION
Acute hyperbilirubinemia is a commonly reported side effect of a number of medicines. [25] [26] [27] The presence of Gilbert's mutation predisposes HIV-infected patients to indinavirinduced hyperbilirubinemia. 25 Genetic variation of UGT1A1 has also been shown to be associated with both irinotecaninduced hyperbilirubinemia and increased drug toxicity. 26, 27 During our phase III trial of tranilast, hyperbilirubinemia was observed in up to 12% of patients. 28 At the time, the etiology of this elevation in serum bilirubin level was unknown. The affected individuals showed no signs of liver damage or overt hemolysis; however, the observed reaction may have been indicative of severe adverse reaction to tranilast. As part of candidate gene variant experimental design, we studied genetic polymorphisms in UGT1A1 in these patients. Our data suggested that an underlying genetic predisposition to Gilbert's syndrome accounts for a major proportion of genetic susceptibility to tranilastinduced hyperbilirubinemia.
Variability in phenotype expression in patients with Gilbert's mutation is well documented, with hyperbilirubinemia developing in patients with the lowest levels of hepatic 3 (a) cases (n ¼ 127, bilirubin levels 42.00 mg/dl); (b) controls (n ¼ 909, bilirubin levels p2.00 mg/dl); (c) super controls, which is a subset of controls (n ¼ 541, bilirubin levels p1.00 mg/dl). UGT activity. 18 It is known that individuals with Gilbert's mutation have low levels of UGT1A1 activity, 18 and tranilast inhibit UGT1A1 activity (data not shown). Thus, patients who are (TA) 7 homozygotes manifest increased susceptibility to hyperbilirubinemia as a consequence of tranilastinduced inhibition of UGT1A1 activity.
Variation in allele frequencies between ethnic groups has implications for worldwide development and surveillance of medicines, and is an important factor to consider when interpreting pharmacogenetic information. Frequencies of the (TA) 6 /(TA) 6 , (TA) 6 /(TA) 7 and TA) 7 /(TA) 7 genotypes were 45, 44 and 11%, respectively, in this Caucasian sample, with a calculated allele frequency for (TA) 7 being 33%. This is in agreement with other reported frequencies in Caucasians. 15, 17, 19 The frequency of the (TA) 7 allele, however, is much lower in Japanese and Asian populations, resulting in 2-3% frequency of (TA) 7 homozygotes. 19 This suggests that the proportion of patients manifesting hyperbilirubinemia after tranilast treatment may be correspondingly lower in Asians.
Attrition of drugs during development due to safety concerns is one of the main problems in the pharmaceutical pipeline. This study showed that tranilast-induced hyperbilirubinemia susceptibility was partly due to the recipient of medicine carrying an allele known to be related to Gilbert's syndrome. It was therefore possible to define a benign condition associated with tranilast-induced hyperbilirubinemia, rather than to suspect patients being susceptible to some unknown, potentially more severe hepatic complications. Rapid identification of an etiology associated with an adverse effect during the course of a Phase III clinical trial demonstrated the power and potential use of pharmacogenetics in clinical studies, especially since the study design is prospective and double blind. Such information is crucial in influencing the regulatory environment surrounding a medicine's progress to commercialization. Unfortunately for the company, the development of tranilast was terminated due to the lack of efficacy in preventing restenosis of coronary vessels. 27 If this drug had good efficacy and reached the marketplace, one would be able to identify the benign hyperbilirubinemic condition by monitoring bilirubin levels both before and during the course of the medicine. Genetic testing of DNA samples would not have been necessary in the management of this mild adverse effect.
In summary, our study clearly demonstrates that genetic variation in UGT1A1 is associated with an increased risk of tranilast-induced hyperbilirubinemia. This genetic variation predisposes individuals to a benign condition, Gilbert's syndrome. The administration of tranilast unmasked the hyperbilirubinemia condition in these patients. The rapid identification of genetic risk factors during the course of a clinical trial demonstrated the power and potential applications of pharmacogenetics in future development of safer medicines.
MATERIALS AND METHODS

Samples
Appropriate ethical committee/IRB approval was obtained to collect blood samples prospectively for genetic studies from individuals participating in PRESTO, a phase III double-blind, placebo-controlled clinical trial of tranilast. 3 Written informed consent to perform genetic analysis was obtained from 1042 Caucasians in the United States who had undergone PTCR for treatment of ischemic heart disease. GlaxoSmithKline Clinical Laboratories performed all clinical testing. The total bilirubin levels were measured before and after tranilast treatment for either 1 or 3 months. DNA was extracted using a Nucleon DNA extraction and purification kit (Tepnel Life Sciences, UK).
Mild hyperbilirubinemia was defined quantitatively as total serum bilirubin levels greater than 2.00 mg/dl. Five individuals (0.5%) preadministration of tranilast and 127 (12%) individuals following administration of tranilast had bilirubin levels greater than 2.00 mg/dl. These 127 individuals were defined as cases in this study. Controls consisted of the remaining 909 subjects, whose total bilirubin levels were equal to or less than 2.00 mg/dl following administration of tranilast. A 'super control' subset of 541 patients was also defined, whose bilirubin level was less than 1.00 mg/dl post-tranilast administration.
Single-Nucleotide
Polymorphism Identification and Genotyping The TA repeat polymorphism (rs3064744) and the G/A substitution (rs4148323), which results in the GLY71Arg amino-acid change within exon 1 of UGT1A1 (MIM191740), were genotyped. The TA repeat polymorphism was genotyped by direct sequencing of PCR products. In brief, PCR primers (5 0 -GAGGTTCTGGAAGTACTTTGC-3 0 and 5 0 -CCAAGCATGCACACCAG-3 0 ) were designed using the sequence of UGT1A1 to amplify a 423 bp DNA fragment. PCR products were sequenced using the ABI Prism BigDye Terminator cycle sequencing chemistry according to the manufacturer's instructions, and analyzed on an ABI 3700 capillary sequencer. The resultant forward and reverse sequence trace files were independently analyzed by two individuals and genotypes were assigned to each sample. The G/A substitution (rs4148323) was genotyped by TaqMan s assay (Perkin-Elmer, USA). Primers (5 0 -CTAGCACCT GACGCCTCGTT-3 0 and 5 0 -CACAGGGTACGTCTTCAAGGT GTA-3 0 ) and probes (5 0 -ATCAGAGACGGAGCAT-3 0 (VIC) and 5 0 -ATCAGAGACAGAGCAT-3 0 (FAM)) were supplied by Invitrogen Life Technologies (UK) and Applied Biosystems (USA), respectively. An ABI 7900HT was used to read fluorescence signals for each sample.
Statistical Analysis
The association between genotypes and phenotype was determined using Fisher's exact test. P-values were determined using the PROC FREQ procedure (http://www.sas. com). PROC FREQ computes exact P-values by generating R Â C tables.
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